Literature DB >> 34296054

Gastrointestinal Malignancies and Venous Thromboembolic Disease: Clinical Significance and Endovascular Interventions.

Xin Li1, Sasan Partovi1, Sameer Gadani1, Charles Martin1, Avi Beck1, Suresh Vedantham2.   

Abstract

Gastrointestinal malignancy encompasses a wide range of disease processes. Its incidence and mortality rate rank among the highest of all cancers. Venous thromboembolic disease is a common complication of gastrointestinal malignancy. Anticoagulation remains the first-line therapy. However, for patients who cannot tolerate or have failed anticoagulation, inferior vena cava (IVC) filter placement may be an option. Furthermore, to improve symptom resolution and reduce the severity of postthrombotic syndrome, catheter-directed thrombolysis (CDT) may be an option. Recent randomized trials including the ATTRACT (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis) trial have shed new light on the efficacy and safety of CDT and related methods. Overall, the decision to proceed with IVC filter placement or CDT must be individualized.

Entities:  

Keywords:  CDT; GI cancer; IVC filter; PCDT; anticoagulation

Year:  2020        PMID: 34296054      PMCID: PMC8294347          DOI: 10.1055/s-0040-1716739

Source DB:  PubMed          Journal:  Dig Dis Interv        ISSN: 2472-8721


  61 in total

1.  Investigating the benefit of adding a vena cava filter to anticoagulation with fondaparinux sodium in patients with cancer and venous thromboembolism in a prospective randomized clinical trial.

Authors:  Myra F Barginear; Richard J Gralla; Thomas P Bradley; Syed S Ali; Iuliana Shapira; Craig Greben; Nanette Nier-Shoulson; Meredith Akerman; Martin Lesser; Daniel R Budman
Journal:  Support Care Cancer       Date:  2012-03-16       Impact factor: 3.603

Review 2.  Epidemiology of the post-thrombotic syndrome.

Authors:  Jean-Philippe Galanaud; Manuel Monreal; Susan R Kahn
Journal:  Thromb Res       Date:  2017-07-24       Impact factor: 3.944

3.  The post-thrombotic syndrome: incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study.

Authors:  Edith M Roumen-Klappe; Martin den Heijer; Mirian C H Janssen; Carine van der Vleuten; Theo Thien; Hub Wollersheim
Journal:  Thromb Haemost       Date:  2005-10       Impact factor: 5.249

4.  Iliofemoral deep venous thrombosis: safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy.

Authors:  H Bjarnason; J R Kruse; D A Asinger; G K Nazarian; C A Dietz; M D Caldwell; N S Key; A T Hirsch; D W Hunter
Journal:  J Vasc Interv Radiol       Date:  1997 May-Jun       Impact factor: 3.464

5.  Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis: Results From the ATTRACT Trial.

Authors:  Elizabeth A Magnuson; Khaja Chinnakondepalli; Katherine Vilain; Clive Kearon; Jim A Julian; Susan R Kahn; Samuel Z Goldhaber; Michael R Jaff; Andrei L Kindzelski; Kevin Herman; Paul S Brady; Karun Sharma; Carl M Black; Suresh Vedantham; David J Cohen
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2019-10-08

Review 6.  Epidemiology and management of venous thromboembolism in patients with cancer.

Authors:  Agnes Y Y Lee
Journal:  Thromb Res       Date:  2003-06-01       Impact factor: 3.944

7.  Complications of therapy for venous thromboembolic disease in patients with brain tumors.

Authors:  J M Levin; D Schiff; J S Loeffler; H A Fine; P M Black; P Y Wen
Journal:  Neurology       Date:  1993-06       Impact factor: 9.910

8.  Inferior vena cava filters in patients with advanced-stage cancer.

Authors:  Asem Mansour; Yousef Ismael; Hikmat Abdel-Razeq
Journal:  Hematol Oncol Stem Cell Ther       Date:  2014-10-06

9.  Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases.

Authors:  Alex J Walker; Tim R Card; Joe West; Colin Crooks; Matthew J Grainge
Journal:  Eur J Cancer       Date:  2012-11-09       Impact factor: 9.162

10.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.